SSI(SZ:002742)2017-04-28 16:00Financial Performance - The company's operating revenue for Q1 2017 was ¥322,756,683.94, representing a 4.79% increase compared to ¥308,012,656.77 in the same period last year[8] - The net profit attributable to shareholders was ¥25,886,044.22, a slight increase of 0.62% from ¥25,725,812.09 year-on-year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 10.02% to ¥23,228,863.57 from ¥25,815,062.09 in the previous year[8] - The company expects net profit attributable to shareholders for the first half of 2017 to range between CNY 64.48 million and CNY 70.63 million, reflecting a growth of 5.00% to 15.00%[21] - The increase in net profit is primarily driven by growth in core business scale and higher revenue contributions from pharmaceutical intermediates and raw materials[21] Cash Flow and Assets - The net cash flow from operating activities was ¥10,612,168.77, a significant improvement from a negative cash flow of ¥13,918,853.17 in the same period last year, marking a 176.24% change[8] - Total assets at the end of the reporting period were ¥2,781,126,020.09, down 0.66% from ¥2,799,486,354.13 at the end of the previous year[8] - The net assets attributable to shareholders decreased by 0.55% to ¥1,296,905,941.68 from ¥1,304,036,676.68 at the end of the previous year[8] - Accounts receivable decreased by 54.91% from CNY 113.63 million to CNY 51.23 million, primarily due to endorsement payments[16] - Construction in progress increased by 1,204.57% from CNY 1.25 million to CNY 16.36 million, mainly due to investments in Baikang Pharmaceutical Phase II and other projects[16] - Other non-current assets rose by 179.81% from CNY 55.14 million to CNY 154.29 million, attributed to prepayments for equipment at Ethiopian San Sheng Pharmaceutical and San Sheng Building Materials[16] - Financial expenses surged by 109.93% from CNY 5.60 million to CNY 11.75 million, due to increased credit model usage and changes in loan structure[16] - Net cash flow from operating activities improved to CNY 10.61 million, a change of -176.24% compared to a negative CNY 13.92 million in the previous period[16] Shareholder Information - The top shareholder, Pan Xianwen, holds 49.94% of the shares, with a total of 107,861,285 shares, of which 106,647,455 are pledged[12] - The total number of ordinary shareholders at the end of the reporting period was 16,247[12] - Minority interests increased by 69.58% from CNY 49.31 million to CNY 83.62 million, mainly due to capital increases from related parties[16] Corporate Actions - The company plans to publicly issue corporate bonds totaling up to CNY 500 million, approved by the board and shareholders[17] - The acquisition of a 60% stake in Chunrui Pharmaceutical for CNY 538 million is underway, with the transfer procedures in progress[18] Return on Equity - The weighted average return on equity was 1.92%, a decrease of 0.16% from 2.08% in the same period last year[8] - The company received government subsidies amounting to ¥254,889.09 during the reporting period[9]